Diagnosis of Vaginitis



FREE PREVIEW Log in or buy this issue to read the full article. AAFP members and paid subscribers get free access to all articles. Subscribe now.


FREE PREVIEW Subscribe or buy this issue. AAFP members and paid subscribers get free access to all articles.

Am Fam Physician. 2000 Sep 1;62(5):1095-1104.

Vaginitis is the most common gynecologic diagnosis in the primary care setting. In approximately 90 percent of affected women, this condition occurs secondary to bacterial vaginosis, vulvovaginal candidiasis or trichomoniasis. Vaginitis develops when the vaginal flora has been altered by introduction of a pathogen or by changes in the vaginal environment that allow pathogens to proliferate. The evaluation of vaginitis requires a directed history and physical examination, with focus on the site of involvement and the characteristics of the vaginal discharge. The laboratory evaluation includes microscopic examination of a saline wet-mount preparation and a potassium hydroxide preparation, a litmus test for the pH of vaginal secretions and a “whiff” test. Metronidazole is the primary treatment for bacterial vaginosis and trichomoniasis. Topical antifungal agents are the first-line treatments for candidal vaginitis.

Vaginitis is the most frequent gynecologic diagnosis encountered by physicians who provide primary care to women.15 Accurate diagnosis can be elusive, complicating treatment.69 Furthermore, the availability of over-the-counter medications increases the likelihood of inappropriate or partial treatment of vaginitis.10

Epidemiology

The prevalence and causes of vaginitis are uncertain, in part because the condition is so often self-diagnosed and self-treated. In addition, vaginitis is frequently asymptomatic or has more than one cause. Most experts believe that up to 90 percent of vaginitis cases are secondary to bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis.4,8 Noninfectious causes include vaginal atrophy, allergies and chemical irritation.

Bacterial Vaginosis

In the United States, bacterial vaginosis is currently the most common cause of vaginitis, accounting for 40 to 50 percent of cases in women of childbearing age.11,12 This infection is believed to be caused by proliferation of a number of organisms, including Gardnerella vaginalis, Mobiluncus species, Mycoplasma hominis and Peptostreptococcus species.1,11

Determining the prevalence of bacterial vaginosis is difficult because one third to three quarters of affected women are asymptomatic.2,12,13 In addition, reported prevalences vary based on the population studied. Bacterial vaginosis has been found in 15 to 19 percent of ambulatory gynecology patients, 10 to 30 percent of pregnant patients and 24 to 40 percent of patients in sexually transmitted disease clinics.8,1115

Even though higher rates of bacterial vaginosis have been reported in sexually transmitted disease clinics and in women with multiple sexual partners, the role of sexual transmission is unclear. Studies indicate that treating the male sexual partner of a woman with bacterial vaginosis is not beneficial and that even women who are not sexually active can have the infection.12,16 Additional risk factors for bacterial vaginosis include the use of intrauterine devices (IUDs), douching and pregnancy.1,1113,17

Evidence suggests that bacterial vaginosis is a risk factor for premature rupture of membranes and preterm labor. Treating the infection in pregnancy decreases this risk.8,1821 Additional possible adverse outcomes include an increased frequency of abnormal Papanicolaou (Pap) smears, pelvic inflammatory disease and endometritis.2224 Vaginal cuff cellulitis, pelvic inflammatory disease and endometritis can occur if invasive gynecologic procedures or surgeries are performed when a patient has bacterial vaginosis.1,8,11

Vulvovaginal Candidiasis

Vulvovaginal candidiasis is the second most common cause of vaginitis in the United States and the most common cause in Europe.1 An estimated 75 percent of women have vulvovaginal candidiasis at some time in life, and approximately 5 percent of women have recurrent episodes.21,2527 Candida albicans is the infecting agent in 80 to 90 percent of patients.8,10 Recently, the frequency of non-albicans species (e.g., Candida glabrata) has increased, possibly secondary to greater use of over-the-counter antifungal products.10

Risk factors for uncomplicated vulvovaginal candidiasis have been difficult to determine.28 Studies have shown that the risk of this infection is increased in women who use oral contraceptive pills, a diaphragm and spermicide, or an IUD.16,29,30 Other risk factors include young age at first intercourse, intercourse more than four times per month and receptive oral sex.25,27,28,31,32 The risk of vulvovaginal candidiasis is also increased in some women who have diabetes, are pregnant or are taking antibiotics.25,28,33

Complications of vulvovaginal candidiasis are rare. Chorioamnionitis in pregnancy and vulvar vestibulitis syndrome have been reported.34,35

Establishing Candida species as the cause of vaginitis can be difficult because as many as 50 percent of asymptomatic women have candidal organisms as part of their endogenous vaginal flora.26 Candidal organisms are not transmitted sexually, and episodes of vulvovaginal candidiasis do not appear to be related to the number of sexual partners.25,27,28 Treating the male partner is unnecessary unless he is uncircumcised or has inflammation of the glans of the penis.36

Recurrent vulvovaginal candidiasis is defined as four or more episodes in a one-year period. It is not clear whether recurrences are secondary to predisposing and/or precipitating factors, sexual transmission, intestinal reservoir or vaginal persistence.37

Trichomoniasis

The protozoan Trichomonas vaginalis, a motile organism with four flagella,3 is the third most common cause of vaginitis. It affects 180 million women worldwide and currently accounts for 10 to 25 percent of vaginal infections.8 The incidence of trichomonal vaginitis is decreasing in most industrialized countries.1

Trichomonads are transmitted sexually and may be identified in 30 to 80 percent of the male sexual partners of infected women.8,38,39 Trichomoniasis is associated with and may act as a vector for other venereal diseases.40,41 Studies indicate that this infection increases the transmission rate of the human immunodeficiency virus.40

Risk factors for trichomoniasis include use of an IUD, cigarette smoking and multiple sexual partners.16,17,42 From 20 to 50 percent of women with trichomoniasis are asymptomatic.8,38 Trichomoniasis may be associated with premature rupture of membranes and preterm delivery.41 Sexual partners should be treated and instructed to avoid sexual intercourse until both partners are cured.36

Pathophysiology

The normal physiologic vaginal discharge comprises vaginal secretions, exfoliated cells and cervical mucus. The frequency of vaginal discharge varies with age, menstrual cycle, pregnancy and use of oral contraceptives.

The normal vaginal environment is characterized by a dynamic interrelationship between Lactobacillus acidophilus and other endogenous flora, estrogen, glycogen, vaginal pH and metabolic by-products of flora and pathogens. L. acidophilus produces hydrogen peroxide, which is toxic to pathogens and keeps the healthy vaginal pH between 3.8 and 4.2. Vaginitis occurs because the vaginal flora has been altered by the introduction of pathogens or changes in the vaginal environment that allow pathogens to proliferate.

Antibiotics, contraceptives, sexual intercourse, douching, stress and hormones can change the vaginal environment and allow pathogens to grow.3,4 In bacterial vaginosis, it is believed that some inciting event decreases the number of hydrogen peroxide–producing L. acidophilus organisms.11 The resultant change in pH allows proliferation of organisms that are normally suppressed, such as G. vaginalis, M. hominis and Mobiluncus species.11,12 These organisms produce metabolic byproducts, such as amines, that further increase the vaginal pH and cause exfoliation of vaginal epithelial cells. The amines are also responsible for the characteristic malodorous discharge in bacterial vaginosis.

Similarly, changes in the vaginal environment, such as an increase in glycogen production in pregnancy or altered estrogen and progesterone levels from the use of oral contraceptives, enhance the adherence of C. albicans to vaginal epithelial cells and facilitate the germination of yeast.26,28 These changes may transform asymptomatic colonization into symptomatic infection. In patients with trichomoniasis, changes in estrogen and progesterone levels, as well as elevations of vaginal pH and glycogen levels, may enhance the growth and virulence of T. vaginalis.42

Evaluation

A patient who complains of vaginal discharge, itching, frequent urination and/or irritation should be evaluated for vaginitis (Figure 1). The first step is to obtain a directed history. The patient should be asked about specific symptoms and their duration, any previous diagnosis and previous treatment and its effects. A general medical review, dermatologic review, social history and contraceptive history can also be helpful.

Diagnosis of Vaginitis

FIGURE 1.

Evaluation of patients with suspected vaginitis. (KOH = potassium hydroxide)

View Large

Diagnosis of Vaginitis


FIGURE 1.

Evaluation of patients with suspected vaginitis. (KOH = potassium hydroxide)

Diagnosis of Vaginitis


FIGURE 1.

Evaluation of patients with suspected vaginitis. (KOH = potassium hydroxide)

It is important to inquire about abdominal or pelvic pain, fever, recurrent or resistant infections, urinary symptoms, menstrual history, pregnancy and sexual practices.43 The nature of the discharge (i.e., amount, consistency, color, odor, accompanying pruritus) may also provide important clues. Dysuria is a common symptom of vaginitis. It is usually external and is defined as pain and burning when urine touches the vulva. In contrast, internal dysuria, defined as pain inside the urethra, is usually a sign of cystitis.5

A physical examination can help to identify the anatomic site of involvement (vulva, vagina or cervix). Inspection of the external genitalia for inflammation, lesions, masses, atrophic tissue and enlarged lymph nodes is important. The physician should also assess the patient for uterine or tubo-ovarian tenderness and perform a speculum examination to detect erythema, edema or lesions. The pooled vaginal discharge should be assessed for color, consistency, volume and adherence to the vaginal walls.

Because the diagnostic tests and treatments for cervicitis are different from those for vaginitis, it is important to differentiate these conditions. Several clues can help to rule out cervical infection as the cause of a vaginal discharge. Almost 90 percent of symptomatic or asymptomatic women with chlamydial cervicitis meet at least two of the following criteria: (1) younger than 24 years, (2) sexual intercourse with a new partner in the previous two months, (3) presence of mucopurulent cervicitis, (4) cervical bleeding induced by swabbing the endocervical mucosa and (5) no form of contraception.44 If cervicitis is suspected, cultures for Chlamydia species and Neisseria gonorrhoeae should be obtained.

If the findings of the history and/or physical examination suggest that the patient has vaginitis, a sample of the vaginal discharge should be obtained for gross and microscopic examination. Standard office examinations include a wet-mount preparation using saline, a slide prepared with 10 percent potassium hydroxide (KOH), a “whiff” test to detect amines and a litmus test of the pH level of vaginal fluid.

WET-MOUNT PREPARATION

A wet-mount preparation is obtained by diluting the vaginal discharge with one or two drops of 0.9 percent normal saline solution and placing it on a slide with a coverslip. Alternatively, the vaginal discharge can be put into a 2-mL test tube containing saline solution and then placed on a slide. The slide is examined microscopically using low power (10×) and high dry power (400×). The scanning of several fields for motile trichomonads has a sensitivity of 60 percent and a specificity of up to 99 percent.45

Microscopic examination of a wet-mount preparation can also detect “clue cells,” which are vaginal epithelial cells that are coated with the coccobacilli. When a skilled examiner performs the search for clue cells, examination of wet-mount preparations can have a sensitivity of 60 percent and a specificity of up to 98 percent for the detection of bacterial vaginosis.4648 The examination may also detect fungal hyphae, increased numbers of polymorphonuclear cells (seen in trichomoniasis) or round parabasal cells (seen in atrophic vaginitis).

KOH PREPARATION AND WHIFF TEST

A second specimen of the vaginal discharge should be placed on a slide with a 10 percent KOH solution. A coverslip is placed on the slide and air- or flame-dried before examination under a microscope using low power.43 This is useful for detecting candidal hyphae, mycelial tangles and spores. The test is positive in 50 to 70 percent of women with candidal infection.49

During preparation of the KOH slide, a whiff test can be performed. The whiff test is positive if a “fishy” or amine odor is detected when KOH is added to the vaginal discharge. The odor results from the liberation of amines and organic acids produced from the alkalization of anaerobic bacteria. A positive whiff test is suggestive of bacterial vaginosis.11

LITMUS TESTING FOR PH

The pH level can be determined by placing litmus paper in the pooled vaginal secretions or against the lateral vaginal wall. The color is then compared to the colors and corresponding pH values on a standard chart. A normal vaginal pH is between 3.8 and 4.2.

Blood and cervical mucus are alkaline and alter the pH of a vaginal sample. A pH greater than 4.5 is found in 80 to 90 percent of patients with bacterial vaginosis and frequently in patients with trichomoniasis.3,49 The pH level is also high in those with atrophic vaginitis.

Differential Diagnosis

The diagnosis of vaginitis is based on the patient's symptoms, the physical examination, the findings of microscopic examination of the wet-mount and KOH preparations, and the results of the pH litmus test. The features of bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis are presented in Table 1.3,8 Women with bacterial vaginosis have a broad spectrum of clinical presentations. The classic presentation is a vaginal discharge with its characteristic odor and a clinical examination that is otherwise normal.

TABLE 1

Features of the Most Common Causes of Vaginitis

Basis of diagnosis Bacterial vaginosis Vulvovaginal candidiasis Trichomoniasis

Signs and symptoms

Thin, off-white discharge Unpleasant “fishy” odor, with odor increasing after sexual intercourse

Thick, white (“cottage cheese”) discharge with no odor Pruritus Dysuria

Copious, malodorous, yellow- green (or discolored) discharge Pruritus Vaginal irritation No symptoms in 20 to 50 percent of affected women

Physical examination

Usually, normal appearance of tissue; discolored discharge with abnormal odor, homogeneous discharge that adheres to vaginal walls

Vulvar and vaginal erythema, edema and fissures Thick, white discharge that adheres to vaginal walls

Vulvar and vaginal edema and erythema “Strawberry” cervix in up to 25 percent of affected women Frothy, purulent discharge

Laboratory tests

Vaginal pH (normal = < 4.5)

Elevated (> 4.5)

Normal

Elevated (> 4.5)

Microscopic examination of wet-mount and KOH preparations of vaginal discharge

“Clue cells” (vaginal epithelial cells coated with coccobacilli) Few lactobacilli Occasional motile, curved rods (Mobiluncus species)

Pseudohyphae, mycelial tangles or budding yeast cells

Motile trichomonads Many polymorphonuclear cells

“Whiff” test (normal = no odor)

Positive

Negative

Can be positive

Additional tests

Amsel's criteria (three of four criteria must be met): provides correct diagnosis in 90 percent of affected women

KOH microscopy Gram stain Culture

DNA probe tests: sensitivity of 90 percent and specificity of 99.8 percent

Culture: sensitivity of 98 percent and specificity of 100 percent

Criteria of Nugent or Spiegel for Gram stain to diagnose bacterial vaginosis Other tests are controversial.


KOH = potassium hydroxide.

Information derived from Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med 1998;13:335–46, and Sobel JD. Vaginitis. N Engl J Med 1997;337:1896–903.

TABLE 1   Features of the Most Common Causes of Vaginitis

View Table

TABLE 1

Features of the Most Common Causes of Vaginitis

Basis of diagnosis Bacterial vaginosis Vulvovaginal candidiasis Trichomoniasis

Signs and symptoms

Thin, off-white discharge Unpleasant “fishy” odor, with odor increasing after sexual intercourse

Thick, white (“cottage cheese”) discharge with no odor Pruritus Dysuria

Copious, malodorous, yellow- green (or discolored) discharge Pruritus Vaginal irritation No symptoms in 20 to 50 percent of affected women

Physical examination

Usually, normal appearance of tissue; discolored discharge with abnormal odor, homogeneous discharge that adheres to vaginal walls

Vulvar and vaginal erythema, edema and fissures Thick, white discharge that adheres to vaginal walls

Vulvar and vaginal edema and erythema “Strawberry” cervix in up to 25 percent of affected women Frothy, purulent discharge

Laboratory tests

Vaginal pH (normal = < 4.5)

Elevated (> 4.5)

Normal

Elevated (> 4.5)

Microscopic examination of wet-mount and KOH preparations of vaginal discharge

“Clue cells” (vaginal epithelial cells coated with coccobacilli) Few lactobacilli Occasional motile, curved rods (Mobiluncus species)

Pseudohyphae, mycelial tangles or budding yeast cells

Motile trichomonads Many polymorphonuclear cells

“Whiff” test (normal = no odor)

Positive

Negative

Can be positive

Additional tests

Amsel's criteria (three of four criteria must be met): provides correct diagnosis in 90 percent of affected women

KOH microscopy Gram stain Culture

DNA probe tests: sensitivity of 90 percent and specificity of 99.8 percent

Culture: sensitivity of 98 percent and specificity of 100 percent

Criteria of Nugent or Spiegel for Gram stain to diagnose bacterial vaginosis Other tests are controversial.


KOH = potassium hydroxide.

Information derived from Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med 1998;13:335–46, and Sobel JD. Vaginitis. N Engl J Med 1997;337:1896–903.

Traditionally, bacterial vaginosis has been diagnosed using Amsel's criteria, with three of the four findings required to establish the diagnosis (Table 2).46 Based on these criteria, 90 percent of women with bacterial vaginosis can be diagnosed correctly.46,47,49

TABLE 2

Amsel's Diagnostic Criteria for Bacterial Vaginosis*

Thin, homogeneous discharge

Positive “whiff” test

“Clue cells” present on microscopy† Vaginal pH > 4.5


*—Three of four criteria must be met; establishes accurate diagnosis of bacterial vaginosis in 90 percent of affected women.

—Highly significant criterion.

Information from Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22.

TABLE 2   Amsel's Diagnostic Criteria for Bacterial Vaginosis*

View Table

TABLE 2

Amsel's Diagnostic Criteria for Bacterial Vaginosis*

Thin, homogeneous discharge

Positive “whiff” test

“Clue cells” present on microscopy† Vaginal pH > 4.5


*—Three of four criteria must be met; establishes accurate diagnosis of bacterial vaginosis in 90 percent of affected women.

—Highly significant criterion.

Information from Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983;74:14–22.

Other investigators have developed criteria to diagnose bacterial vaginosis using a gram-stained vaginal smear3,5052  (Tables 350  and 4)51. Evaluations of tests for bacterial vaginosis have shown that the Gram stain is better than gasliquid chromatography, G. vaginalis cultures or an assay for proline aminopeptidase.48

TABLE 3

Nugent's Diagnostic Criteria for Bacterial Vaginosis

Scoring system (zero to 7+)* is a weighted combination of the following bacterial morphotypes:

A. Lactobacillus acidophilus (large gram-positive rods) B. Gardnerella vaginalis and Bacteroides species (small gram-variable or gram-negative rods) C. Mobiluncus species (curved gram-variable rods)

The total score is the sum of the weighted quantity of the three bacterial morphotypes.

Scoring for each of the above bacterial morphotypes:

Zero = No morphotypes per oil-immersion field

1+ = Less than one morphotype per oil-immersion field 2+ = One to four morphotypes per oil-immersion field 3+ = Five to 30 morphotypes per oil-immersion field 4+ = More than 30 morphotypes per oil-immersion field


*—For the combined score (A + B + C), zero to 3 represents normal flora, 4 to 6 represents indeterminate, and 7 or higher is diagnostic of bacterial vaginosis.

Information from Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297–301.

TABLE 3   Nugent's Diagnostic Criteria for Bacterial Vaginosis

View Table

TABLE 3

Nugent's Diagnostic Criteria for Bacterial Vaginosis

Scoring system (zero to 7+)* is a weighted combination of the following bacterial morphotypes:

A. Lactobacillus acidophilus (large gram-positive rods) B. Gardnerella vaginalis and Bacteroides species (small gram-variable or gram-negative rods) C. Mobiluncus species (curved gram-variable rods)

The total score is the sum of the weighted quantity of the three bacterial morphotypes.

Scoring for each of the above bacterial morphotypes:

Zero = No morphotypes per oil-immersion field

1+ = Less than one morphotype per oil-immersion field 2+ = One to four morphotypes per oil-immersion field 3+ = Five to 30 morphotypes per oil-immersion field 4+ = More than 30 morphotypes per oil-immersion field


*—For the combined score (A + B + C), zero to 3 represents normal flora, 4 to 6 represents indeterminate, and 7 or higher is diagnostic of bacterial vaginosis.

Information from Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol 1991;29:297–301.

TABLE 4

Spiegel's Diagnostic Criteria for Bacterial Vaginosis

Normal: Gram stain shows a predominance of Lactobacillus acidophilus (3+ or 4+), with or without Gardnerella vaginalis.

Bacterial vaginosis: Gram stain shows mixed flora (gram-positive, gram-negative or gram-variable bacteria) and absent or decreased

L. acidophilus (zero to 2+). A. L. acidophilus (large gram-positive bacilli) B. G. vaginalis (small gram-variable rods)

Scoring for each of the above bacterial morphotypes:

Zero = No morphotypes per oil-immersion field

1+ = Less than one morphotype per oil-immersion field 2+ = One to five morphotypes per oil-immersion field 3+ = Six to 30 morphotypes per oil-immersion field 4+ = More than 30 morphotypes per oil-immersion field


Information from Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. J Clin Microbiol 1983;18:170–7.

TABLE 4   Spiegel's Diagnostic Criteria for Bacterial Vaginosis

View Table

TABLE 4

Spiegel's Diagnostic Criteria for Bacterial Vaginosis

Normal: Gram stain shows a predominance of Lactobacillus acidophilus (3+ or 4+), with or without Gardnerella vaginalis.

Bacterial vaginosis: Gram stain shows mixed flora (gram-positive, gram-negative or gram-variable bacteria) and absent or decreased

L. acidophilus (zero to 2+). A. L. acidophilus (large gram-positive bacilli) B. G. vaginalis (small gram-variable rods)

Scoring for each of the above bacterial morphotypes:

Zero = No morphotypes per oil-immersion field

1+ = Less than one morphotype per oil-immersion field 2+ = One to five morphotypes per oil-immersion field 3+ = Six to 30 morphotypes per oil-immersion field 4+ = More than 30 morphotypes per oil-immersion field


Information from Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. J Clin Microbiol 1983;18:170–7.

Women with vulvovaginal candidiasis frequently complain of pruritus, vaginal irritation and dysuria. Vulvovaginal itching generally is not a normal finding in healthy women; if this symptom is present, other dermatologic conditions (e.g., lichen sclerosis and, rarely, vulvar cancer) should also be considered, especially in the absence of candidal infection.5,43

In vulvovaginal candidiasis, the discharge is usually white and thick, with no odor and a normal pH. Women with candidiasis can have vulvar and vaginal erythema and, occasionally, scaling and fissures of vulvar tissue.8,49 Microscopic examinations of wet-mount and KOH preparations are positive in 50 to 70 percent of patients with candidal infections.49 In patients with a negative microscopic examination but symptoms compatible with yeast vaginitis, a Gram stain or a culture using Nickerson's medium or Sabouraud's dextrose agar may be helpful.4,5,28 Other tests, such as the Pap smear or the latex agglutination test, provide no advantage over microscopic techniques.21,26,53

Classic manifestations of vaginal trichomoniasis include a purulent, frothy, yellow discharge with an abnormal odor, pruritus and dysuria. The physical examination may reveal superficial vulvovaginal erythema, and the discharge usually has an elevated pH.5,49

For microscopic examination of the vaginal discharge, warming the slide and decreasing the intensity of substage lighting are ways to increase sensitivity for trichomonads.43 Additional testing may include cultures using Diamond's medium, which has a sensitivity of 95 percent for the diagnosis of trichomoniasis. Tests using DNA probes and polymerase chain reaction tests have high sensitivity and specificity.54 Cultures or other tests should be performed when the index of suspicion for trichomoniasis is high and examination of the wet-mount preparation is negative.

The treatments of bacterial vaginosis, vulvovaginal candidiasis and trichomoniasis are summarized in Table 5.36,55,56  Topical antifungal agents for the treatment of vaginitis are listed in Table 6.57

TABLE 5

Treatments of the Most Common Causes of Vaginitis

Treatment regimens Bacterial vaginosis Vulvovaginal candidiasis Trichomoniasis

Acute regimens

Metronidazole (Flagyl), 500 mg orally twice daily for seven days*

Topical antifungal agents† (see Table 6) Fluconazole (Diflucan), 150 mg orally one time

Metronidazole, 2 g orally in a single dose‡

Clindamycin phosphate vaginal cream 2 percent (Cleocin Vaginal), one full applicator (5 g) intravaginally each night for 7 days* (Note that oil-based cream may weaken condoms and diaphragms.)

Metronidazole gel 0.75 percent (Metrogel-Vaginal), one full applicator (5 g) intravaginally twice daily for 5 days*

Alternative regimens

Metronidazole, 2 g orally in a single dose Clindamycin (Cleocin), 300 mg orally twice daily for 7 days

Boric acid powder in size-0 gelatin capsules intravaginally once or twice daily for 2 weeks§

Metronidazole, 500 mg orally twice daily for 7 days

Pregnancy

Metronidazole, 250 mg orally three times daily for 7 days (recommended regimen)∥

Only topical azole agents intravaginally for 7 to 10 days

Metronidazole, 2 g orally in a single dose (usually not recommended in first trimester)

Alternative regimens for pregnancy

Metronidazole, 2 g orally in a single dose∥ Clindamycin, 300 mg orally twice daily for 7 days∥

Metronidazole gel 0.75 percent, one full applicator (5 g) intravaginally twice daily for 5 days (acceptable only in women who have not had a previous premature delivery)

Recurrence¶

Retreat with an alternative regimen.

For four or more episodes of symptomatic vulvovaginal candidiasis annually: initial acute intravaginal regimen for 10 to 14 days followed immediately by maintenance regimen for at least 6 months (e.g., ketoconazole [Nizoral], 100 mg orally once daily)

Metronidazole, 2 g orally once daily for 3 to 5 days (Note that treatment of sexual partners increases cure rate.)


*—Cure rates for these regimens for bacterial vaginosis range from 74 to 85 percent.

† —Cure rates for selected topical antifungal agents (e.g., polyenes, imidazoles) range from 75 to 90 percent.

‡— Cure rate for acute therapy is 90 to 95 percent. Single-dose therapy is associated with better compliance. Ensuring treatment of sexual partners will increase cure rate. Topical therapy secondary to nontherapeutic levels in the urethra and perivaginal glands should not be used. Alcohol use should be avoided during metronidazole therapy and for 24 hours after treatment.

§— Although this treatment is not included in the recommendations from the Centers for Disease Control and Prevention, a 98 percent cure rate has been reported for its use in patients who failed commonly used treatments. 56

—Lower doses of medications are recommended during pregnancy; use in first trimester should be avoided. Use of clindamycin phosphate vaginal cream is not recommended during pregnancy.

—All cases of recurrent vaginitis should be confirmed by culture before maintenance therapy is initiated. Information from references 36, 55 and 56.

TABLE 5   Treatments of the Most Common Causes of Vaginitis

View Table

TABLE 5

Treatments of the Most Common Causes of Vaginitis

Treatment regimens Bacterial vaginosis Vulvovaginal candidiasis Trichomoniasis

Acute regimens

Metronidazole (Flagyl), 500 mg orally twice daily for seven days*

Topical antifungal agents† (see Table 6) Fluconazole (Diflucan), 150 mg orally one time

Metronidazole, 2 g orally in a single dose‡

Clindamycin phosphate vaginal cream 2 percent (Cleocin Vaginal), one full applicator (5 g) intravaginally each night for 7 days* (Note that oil-based cream may weaken condoms and diaphragms.)

Metronidazole gel 0.75 percent (Metrogel-Vaginal), one full applicator (5 g) intravaginally twice daily for 5 days*

Alternative regimens

Metronidazole, 2 g orally in a single dose Clindamycin (Cleocin), 300 mg orally twice daily for 7 days

Boric acid powder in size-0 gelatin capsules intravaginally once or twice daily for 2 weeks§

Metronidazole, 500 mg orally twice daily for 7 days

Pregnancy

Metronidazole, 250 mg orally three times daily for 7 days (recommended regimen)∥

Only topical azole agents intravaginally for 7 to 10 days

Metronidazole, 2 g orally in a single dose (usually not recommended in first trimester)

Alternative regimens for pregnancy

Metronidazole, 2 g orally in a single dose∥ Clindamycin, 300 mg orally twice daily for 7 days∥

Metronidazole gel 0.75 percent, one full applicator (5 g) intravaginally twice daily for 5 days (acceptable only in women who have not had a previous premature delivery)

Recurrence¶

Retreat with an alternative regimen.

For four or more episodes of symptomatic vulvovaginal candidiasis annually: initial acute intravaginal regimen for 10 to 14 days followed immediately by maintenance regimen for at least 6 months (e.g., ketoconazole [Nizoral], 100 mg orally once daily)

Metronidazole, 2 g orally once daily for 3 to 5 days (Note that treatment of sexual partners increases cure rate.)


*—Cure rates for these regimens for bacterial vaginosis range from 74 to 85 percent.

† —Cure rates for selected topical antifungal agents (e.g., polyenes, imidazoles) range from 75 to 90 percent.

‡— Cure rate for acute therapy is 90 to 95 percent. Single-dose therapy is associated with better compliance. Ensuring treatment of sexual partners will increase cure rate. Topical therapy secondary to nontherapeutic levels in the urethra and perivaginal glands should not be used. Alcohol use should be avoided during metronidazole therapy and for 24 hours after treatment.

§— Although this treatment is not included in the recommendations from the Centers for Disease Control and Prevention, a 98 percent cure rate has been reported for its use in patients who failed commonly used treatments. 56

—Lower doses of medications are recommended during pregnancy; use in first trimester should be avoided. Use of clindamycin phosphate vaginal cream is not recommended during pregnancy.

—All cases of recurrent vaginitis should be confirmed by culture before maintenance therapy is initiated. Information from references 36, 55 and 56.

TABLE 6

Topical Antifungal Therapy for Vaginitis

Butoconazole 2 percent cream (Femstat 3, Mycelex-3), 5 g per day intravaginally for 3 days*†

Clotrimazole 1 percent cream (Mycelex-7), 5 g per day intravaginally for 7 to 14 days*†

Clotrimazole 100-mg vaginal tablet (Gyne-Lotrimen, Mycelex), one tablet per day intravaginally for 7 days*

Clotrimazole 100-mg vaginal tablet, two tablets per day intravaginally for 3 days*

Clotrimazole 500-mg vaginal tablet (Mycelex-G), one tablet intravaginally in a single application*

Miconazole 2 percent cream (Monistat 7), 5 g per day intravaginally for 7 days*†

Miconazole 200-mg vaginal suppository (Monistat 3), one suppository per day for 3 days*†

Miconazole 100-mg vaginal suppository (Monistat 7), one suppository per day for 7 days*†

Nystatin 100,000-unit vaginal tablet (Mycostatin), one tablet per day intravaginally for 14 days

Tioconazole 6.5 percent ointment (Vagistat-1), 5 g intravaginally in a single application*†

Terconazole 0.4 percent cream (Terazol 7), 5 g per day intravaginally for 7 days*

Terconazole 0.8 percent cream (Terazol 3), 5 g per day intravaginally for 3 days*

Terconazole 80-mg vaginal suppository (Terazol 3), one suppository per day for 3 days*


*—These creams and suppositories are oil-based and might weaken latex condoms and diaphragms. Additional information is available on condom product labelings.

†—Over-the-counter preparations.

Adapted from 1998 guidelines for treatment of sexually transmitted diseases. Retrieved June 19, 2000, from the World Wide Web: http://www.cdc.gov/nchstp/dstd/1998_STD_guidelines_for_the_treatment.htm.

TABLE 6   Topical Antifungal Therapy for Vaginitis

View Table

TABLE 6

Topical Antifungal Therapy for Vaginitis

Butoconazole 2 percent cream (Femstat 3, Mycelex-3), 5 g per day intravaginally for 3 days*†

Clotrimazole 1 percent cream (Mycelex-7), 5 g per day intravaginally for 7 to 14 days*†

Clotrimazole 100-mg vaginal tablet (Gyne-Lotrimen, Mycelex), one tablet per day intravaginally for 7 days*

Clotrimazole 100-mg vaginal tablet, two tablets per day intravaginally for 3 days*

Clotrimazole 500-mg vaginal tablet (Mycelex-G), one tablet intravaginally in a single application*

Miconazole 2 percent cream (Monistat 7), 5 g per day intravaginally for 7 days*†

Miconazole 200-mg vaginal suppository (Monistat 3), one suppository per day for 3 days*†

Miconazole 100-mg vaginal suppository (Monistat 7), one suppository per day for 7 days*†

Nystatin 100,000-unit vaginal tablet (Mycostatin), one tablet per day intravaginally for 14 days

Tioconazole 6.5 percent ointment (Vagistat-1), 5 g intravaginally in a single application*†

Terconazole 0.4 percent cream (Terazol 7), 5 g per day intravaginally for 7 days*

Terconazole 0.8 percent cream (Terazol 3), 5 g per day intravaginally for 3 days*

Terconazole 80-mg vaginal suppository (Terazol 3), one suppository per day for 3 days*


*—These creams and suppositories are oil-based and might weaken latex condoms and diaphragms. Additional information is available on condom product labelings.

†—Over-the-counter preparations.

Adapted from 1998 guidelines for treatment of sexually transmitted diseases. Retrieved June 19, 2000, from the World Wide Web: http://www.cdc.gov/nchstp/dstd/1998_STD_guidelines_for_the_treatment.htm.

The Authors

MARI E. EGAN, M.D., is instructor and preclinical coordinator in the Department of Family Medicine at Northwestern University Medical School, Chicago. She received her medical degree from Rush Medical College of Rush University, Chicago, and completed a residency at Providence Family Medicine Residency, affiliated with the University of Washington, Seattle. Dr. Egan is currently completing a master of medical education degree at the University of Illinois, Chicago.

MARTIN S. LIPSKY, M.D., is professor and chair of the Department of Family Medicine at Northwestern University Medical School and Evanston Northwestern Healthcare. Dr. Lipsky received his medical degree from the Medical College of Pennsylvania, Philadelphia, and completed a family medicine residency at the University of California, Irvine, College of Medicine.

Address correspondence to Mari E. Egan, M.D., Northwestern University Medical School, Department of Family Medicine, 303 E. Chicago Ave., Chicago, IL 60611. Reprints are not available from the authors.

The authors thank Mark Potter, M.D., Provident-Loyola Family Medicine Residency, Chicago, for reviewing the manuscript, and Daved Shanks, Chicago, for assistance in preparing Figure 1.

REFERENCES

1. Kent HL. Epidemiology of vaginitis. Am J Obstet Gynecol. 1991;165:1168–76.

2. McCue JD. Evaluation and management of vaginitis. An update for primary care practitioners. Arch Intern Med. 1989;149:565–8.

3. Carr PL, Felsenstein D, Friedman RH. Evaluation and management of vaginitis. J Gen Intern Med. 1998;13:335–46.

4. Sobel JD. Vulvovaginitis in healthy women. Compr Ther. 1999;25:335–46.

5. Haefner HK. Current evaluation and management of vulvovaginitis. Clin Obstet Gynecol. 1999;42:184–95.

6. Eschenbach DA, Hillier SL. Advances in diagnostic testing for vaginitis and cervicitis. J Reprod Med. 1989;34:555–64.

7. Schaaf VM, Perez-Stable EJ, Borchardt K. The limited value of symptoms and signs in the diagnosis of vaginal infections. Arch Intern Med. 1990;150:1929–33.

8. Sobel JD. Vaginitis. N Engl J Med. 1997;337:1896–903.

9. Berg AO, Heidrich FE, Fihn SD, Bergman JJ, Wood RW, Stamm WE, et al. Establishing the cause of genitourinary symptoms in women in a family practice. Comparison of clinical examination and comprehensive microbiology. JAMA. 1984;251:620–5.

10. Horowitz BJ, Giaquinta D, Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 1992;32:248–55.

11. Hill GB. The microbiology of bacterial vaginosis. Am J Obstet Gynecol. 1993;169:450–4.

12. Hay PE. Recurrent bacterial vaginosis. Dermatol Clin. 1998;16:769–73,xii–xiii.

13. Sobel J. Bacterial vaginosis. Br J Clin Pract Infect. 1990;71(suppl):65–9.

14. Hill LH, Ruparelia H, Embil JA. Nonspecific vaginitis and other genital infections in three clinic populations. Sex Transm Dis. 1983;10:114–8.

15. Bump RC, Buesching WJ 3d. Bacterial vaginosis in virginal and sexually active adolescent females: evidence against exclusive sexual transmission. Am J Obstet Gynecol. 1988;158:935–9.

16. Barbone F, Austin H, Louv WC, Alexander WJ. A follow-up study of methods of contraception, sexual activity, and rates of trichomoniasis, candidiasis, and bacterial vaginosis. Am J Obstet Gynecol. 1990;163:510–4.

17. Haukkamaa M, Stranden P, Jousimies-Somer H, Siitonen A. Bacterial flora of the cervix in women using different methods of contraception. Am J Obstet Gynecol. 1986;154:520–4.

18. Hay PE, Lamont RF, Taylor-Robinson D, Morgan DJ, Ison C, Pearson J. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ. 1994;308:295–8.

19. Hillier SL, Nugent RP, Eschenbach DA, Krohn MA, Gibbs RS, Martin DH, et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med. 1995;333:1737–42.

20. Hauth JC, Goldenberg RL, Andrews W W, DuBard MB, Cooper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med. 1995;333:1732–6.

21. Monif GR. Classification and pathogenesis of vulvovaginal candidiasis. Am J Obstet Gynecol. 1985;152:935–9.

22. Eltabbakh GH, Eltabbakh GD, Broekhuizen FF, Griner BT. Value of wet mount and cervical cultures at the time of cervical cytology in asymptomatic women. Obstet Gynecol. 1995;85:499–503.

23. Soper DE, Brockwell MJ, Dalton HP, Johnson D. Observations concerning the microbial etiology of acute salpingitis. Am J Obstet Gynecol. 1994;170:1008–14.

24. Korn AP, Bolan G, Padian N, Ohm-Smith M, Schachter J, Landers DV. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol. 1995;85:387–90.

25. Foxman B. The epidemiology of vulvovaginal candidiasis: risk factors. Am J Public Health. 1990;80:329–31.

26. Sobel JD. Candidal vulvovaginitis. Clin Obstet Gynecol. 1993;36:153–65.

27. Geiger AM, Foxman B. Risk factors for vulvovaginal candidiasis: a case-control study among university students. Epidemiology. 1996;7:182–7.

28. Sobel JD, Faro S, Force RW, Foxman B, Ledger WJ, Nyirjesy PR, et al. Vulvovaginal candidiasis: epidemiologic, diagnostic, and therapeutic considerations. Am J Obstet Gynecol. 1998;178:203–11.

29. Spinillo A, Capuzzo E, Nicola S, Baltaro F, Ferrari A, Monaco A. The impact of oral contraception on vulvovaginal candidiasis. Contraception. 1995;51:293–7.

30. Hooton TM, Roberts PL, Stamm WE. Effects of recent sexual activity and use of a diaphragm on the vaginal microflora. Clin Infect Dis. 1994;19:274–8.

31. Skinner CJ, Stokes J, Kirlew Y, Kavanagh J, Forster GE. A case-controlled study of the sexual health needs of lesbians. Genitourin Med. 1996;72:277–80.

32. Eckert LO, Hawes SE, Stevens CE, Koutsky LA, Eschenbach DA, Holmes KK. Vulvovaginal candidiasis: clinical manifestations, risk factors, management algorithm. Obstet Gynecol. 1998;92:757–65.

33. Spinillo A, Capuzzo E, Acciano S, De Santolo A, Zara F. Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol. 1999;180:14–7.

34. Cotch MF, Hillier SL, Gibbs RS, Eschenbach DA. Epidemiology and outcomes associated with moderate to heavy Candida colonization during pregnancy. Vaginal Infections and Prematurity Study Group. Am J Obstet Gynecol. 1998;178:374–80.

35. Pagano R. Vulvar vestibulitis syndrome: an often unrecognized cause of dyspareunia. Aust N Z J Obstet Gynaecol. 1999;39:79–83.

36. 1998 guidelines for treatment of sexually transmitted diseases. Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 1998;47:1–111.

37. Sobel JD. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992;14(suppl 1):S148–53.

38. Lossick JG, Kent HL. Trichomoniasis: trends in diagnosis and management. Am J Obstet Gynecol. 1991;165:1217–22.

39. Petrin D, Delgaty K, Bhatt R, Garber G. Clinical and microbiological aspects of Trichomonas vaginalis. Clin Microbiol Rev. 1998;11:300–17.

40. Laga M, Manoka AT, Kivuvu M, Malele B, Tuliza M, Nzila N, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS. 1993;7:95–102.

41. Cotch MF, Pastorek JG 2d, Nugent RP, Yerg DE, Martin DH, Eschenbach DA. Demographic and behavioral predictors of Trichomonas vaginalis infection among pregnant women. The Vaginal Infections and Prematurity Study Group Obstet Gynecol. 1991;78:1087–92.

42. Hammill HA. Trichomonas vaginalis. Obstet Gynecol Clin North Am. 1989;16:531–40.

43. Reilly BM. Practical strategies in outpatient medicine. 2d ed. Philadelphia: Saunders, 1991:1016–46.

44. Handsfield HH, Jasman LL, Roberts PL, Hanson V W, Kothenbeutel RL, Stamm WE. Criteria for selective screening for Chlamydia trachomatis infection in women attending family planning clinics. JAMA. 1986;255:1730–4.

45. Krieger JN, Tam MR, Stevens CE, Nielsen IO, Hale J, Kiviat NB, et al. Diagnosis of trichomoniasis. Comparison of conventional wet-mount examination with cytologic studies, cultures, and monoclonal antibody staining of direct specimens. JAMA. 1988;259:1223–7.

46. Amsel R, Totten PA, Spiegel CA, Chen KC, Eschenbach D, Holmes KK. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74:14–22.

47. Thomason JL, Gelbart SM, Anderson RJ, Walt AK, Osypowski PJ, Broekhuizen FF. Statistical evaluation of diagnostic criteria for bacterial vaginosis. Am J Obstet Gynecol. 1990;162:155–60.

48. Krohn MA, Hillier SL, Eschenbach DA. Comparison of methods for diagnosing bacterial vaginosis among pregnant women. J Clin Microbiol. 1989;27:1266–71.

49. ACOG technical bulletin. Vaginitis. Number 226—July 1996 (replaces no. 221, March 1996). Committee on Technical Bulletins of the American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet. 1996;54:293–302.

50. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of Gram stain interpretation. J Clin Microbiol. 1991;29:297–301.

51. Spiegel CA, Amsel R, Holmes KK. Diagnosis of bacterial vaginosis by direct Gram stain of vaginal fluid. J Clin Microbiol. 1983;18:170–7.

52. Mazzulli T, Simor AE, Low DE. Reproducibility of interpretation of Gram-stained vaginal smears for the diagnosis of bacterial vaginosis. J Clin Microbiol. 1990;28:1506–8.

53. Sobel JD. Pathophysiology of vulvovaginal candidiasis. J Reprod Med. 1989;34:572–9.

54. DeMeo LR, Draper DL, McGregor JA, Moore DF, Peter CR, Kapernick PS, et al. Evaluation of a deoxyribonucleic acid probe for the detection of Trichomonas vaginalis in vaginal secretions. Am J Obstet Gynecol. 1996;174:1339–42.

55. Joesoef MR, Schmid GP, Hillier SL. Bacterial vaginosis: review of treatment options and potential clinical indications for therapy. Clin Infect Dis. 1999;28(suppl 1):S57–65.

56. Jovanovic R, Congema E, Nguyen HT. Antifungal agents vs. boric acid for treating chronic mycotic vulvovaginitis. J Reprod Med. 1991;36:593–7.

57. 1998 guidelines for treatment of sexually transmitted diseases. Retrieved June 19, 2000, from the World Wide Web: http://www.cdc.gov/nchstp/dstd/1998_STD_Guidelines/1998_guidelines_for_the_treatment.htm.

Members of various family practice departments develop articles for “Problem-Oriented Diagnosis.” This article is one in a collaborative series coordinated by David R. Rudy, M.D., M.P.H., from the Department of Family Medicine at the Chicago Medical School of Finch University of Health Sciences, and Martin S. Lipsky, M.D., from the Department of Family Medicine at Northwestern University Medical School, Chicago.


Copyright © 2000 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.

Want to use this article elsewhere? Get Permissions


Article Tools

  • Print page
  • Share this page
  • AFP CME Quiz

Information From Industry

More in AFP

More in Pubmed

Navigate this Article